These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8999452)

  • 41. Increased 18F-FDG uptake of hepatocellular carcinoma on positron emission tomography independently predicts tumor recurrence in liver transplant patients.
    Kornberg A; Küpper B; Thrum K; Katenkamp K; Steenbeck J; Sappler A; Habrecht O; Gottschild D
    Transplant Proc; 2009; 41(6):2561-3. PubMed ID: 19715974
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FDG PET/CT early dynamic blood flow and late standardized uptake value determination in hepatocellular carcinoma.
    Bernstine H; Braun M; Yefremov N; Lamash Y; Carmi R; Stern D; Steinmetz A; Sosna J; Groshar D
    Radiology; 2011 Aug; 260(2):503-10. PubMed ID: 21555347
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspective.
    Cheung TT; Ho CL; Lo CM; Chen S; Chan SC; Chok KS; Fung JY; Yan Chan AC; Sharr W; Yau T; Poon RT; Fan ST
    J Nucl Med; 2013 Feb; 54(2):192-200. PubMed ID: 23321459
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT.
    Talbot JN; Gutman F; Fartoux L; Grange JD; Ganne N; Kerrou K; Grahek D; Montravers F; Poupon R; Rosmorduc O
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1285-9. PubMed ID: 16802155
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment.
    Okazumi S; Isono K; Enomoto K; Kikuchi T; Ozaki M; Yamamoto H; Hayashi H; Asano T; Ryu M
    J Nucl Med; 1992 Mar; 33(3):333-9. PubMed ID: 1311035
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multiparametric FDG-PET/MRI of Hepatocellular Carcinoma: Initial Experience.
    Hectors SJ; Wagner M; Besa C; Huang W; Taouli B
    Contrast Media Mol Imaging; 2018; 2018():5638283. PubMed ID: 30402045
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.
    Chalaye J; Costentin CE; Luciani A; Amaddeo G; Ganne-Carrié N; Baranes L; Allaire M; Calderaro J; Azoulay D; Nahon P; Seror O; Mallat A; Soussan M; Duvoux C; Itti E; Nault JC
    J Hepatol; 2018 Aug; 69(2):336-344. PubMed ID: 29518452
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [18F-Fluorodeoxyglucose uptake in hepatocellular carcinoma on positron emission tomography correlates with alpha-fetoprotein].
    Shang JB; Li YH; Liu FY; Zeng QL; Wang JY; He XF; Chen Y
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Jun; 24(6):697-9. PubMed ID: 15201094
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine.
    Derlon JM; Petit-Taboué MC; Chapon F; Beaudouin V; Noël MH; Creveuil C; Courtheoux P; Houtteville JP
    Neurosurgery; 1997 Feb; 40(2):276-87; discussion 287-8. PubMed ID: 9007859
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma.
    Sager S; Akgün E; Uslu-Beşli L; Asa S; Akovali B; Sahin O; Yeyin N; Demir M; Abuqbeitah M; Gülsen F; Sayman H; Sönmezoglu K
    Nucl Med Commun; 2019 May; 40(5):461-468. PubMed ID: 30896544
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation.
    Lin CY; Liao CW; Chu LY; Yen KY; Jeng LB; Hsu CN; Lin CL; Kao CH
    Clin Nucl Med; 2017 Apr; 42(4):e183-e187. PubMed ID: 28114226
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Power Doppler sonography: evaluation of hepatocellular carcinoma after treatment with transarterial embolization or percutaneous ethanol injection therapy.
    Koito K; Namieno T; Ichimura T; Hirokawa N; Syonai T; Hareyama M; Katsuramaki T; Hirata K; Nishi M
    AJR Am J Roentgenol; 2000 Feb; 174(2):337-41. PubMed ID: 10658701
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular mechanisms of [18F]fluorodeoxyglucose accumulation in liver cancer.
    Izuishi K; Yamamoto Y; Mori H; Kameyama R; Fujihara S; Masaki T; Suzuki Y
    Oncol Rep; 2014 Feb; 31(2):701-6. PubMed ID: 24297035
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Percutaneous ethanol injection therapy (PEIT) for hepatocellular carcinoma (HCC).
    Mueller PR
    Jpn J Cancer Res; 1995 Nov; 86(11):inside front cover. PubMed ID: 8567388
    [No Abstract]   [Full Text] [Related]  

  • 55. Diagnosis of Hepatocellular Carcinoma Using C11 Choline PET/CT: Comparison with F18 FDG, ContrastEnhanced MRI and MDCT.
    Chotipanich C; Kunawudhi A; Promteangtrong C; Tungsuppawattanakit P; Sricharunrat T; Wongsa P
    Asian Pac J Cancer Prev; 2016; 17(7):3569-73. PubMed ID: 27510010
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Needle tract implantation of hepatocellular carcinoma after percutaneous ethanol injection.
    Ishii H; Okada S; Okusaka T; Yoshimori M; Nakasuka H; Shimada K; Yamasaki S; Nakanishi Y; Sakamoto M
    Cancer; 1998 May; 82(9):1638-42. PubMed ID: 9576282
    [TBL] [Abstract][Full Text] [Related]  

  • 57. (4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies.
    Baek S; Mueller A; Lim YS; Lee HC; Lee YJ; Gong G; Kim JS; Ryu JS; Oh SJ; Lee SJ; Bacher-Stier C; Fels L; Koglin N; Schatz CA; Dinkelborg LM; Moon DH
    J Nucl Med; 2013 Jan; 54(1):117-23. PubMed ID: 23232273
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 18F-FDG-PET and histopathology in 131I-lipiodol treatment for primary liver cancer.
    Risse JH; Pauleit D; Bender H; Rabe C; Fischer HP; Biersack HJ; Bucerius J
    Cancer Biother Radiopharm; 2009 Aug; 24(4):445-52. PubMed ID: 19694579
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radioembolization with
    Ho CL; Chen S; Cheung SK; Leung YL; Cheng KC; Wong KN; Wong YH; Leung TWT
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2110-2121. PubMed ID: 29948107
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study.
    Hyun SH; Eo JS; Lee JW; Choi JY; Lee KH; Na SJ; Hong IK; Oh JK; Chung YA; Song BI; Kim TS; Kim KS; Moon DH; Yun M
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1638-45. PubMed ID: 26936852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.